CJC-1295 with DAC in Canada: A Research Guide to the Long-Acting GHRH Analogue

Why CJC-1295 with DAC deserves its own guide#

Canadian searches for CJC-1295 usually arrive at supplier pages that collapse two different molecules into one product description. The reader sees "CJC-1295" and is rarely told whether the vial contains the long-acting albumin-binding analogue or the short-acting modified GRF fragment. That ambiguity matters for research design, for endpoint interpretation, and for documentation standards.

This guide treats CJC-1295 with DAC as a defined experimental tool with a specific pharmacokinetic identity. It is not a generic growth-hormone peptide, nor is it interchangeable with Modified GRF (1-29), Sermorelin, or Ipamorelin. The useful questions are narrower: what is the molecule, how does the DAC extension change its behaviour in circulation, what does the evidence actually say about half-life and axis stimulation, and how should a Canadian lab evaluate a supplier listing before placing an order?

We do not provide dosing instructions, cycle design, injection protocols, or body-composition recommendations. The article is written for researchers who need to separate pharmacology from marketing, and who want to understand why the DAC distinction is not a footnote.

What CJC-1295 with DAC is at the molecular level#

CJC-1295 with DAC is a synthetic analogue of human growth-hormone-releasing factor, also called growth-hormone-releasing hormone (GHRH or GRF). The native hormone is a 44-amino-acid peptide that stimulates somatotroph cells in the anterior pituitary to release growth hormone. Its therapeutic limitation has always been brevity: native GHRH is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) and has a plasma half-life measured in minutes.

The research solution embodied in CJC-1295 with DAC is twofold: first, modify the GRF(1-29) core to resist proteolytic degradation; second, attach a drug affinity complex (DAC) that forms a covalent bond with albumin in circulation, dramatically extending exposure.

The modified GRF(1-29) core#

The base sequence of CJC-1295 with DAC is a tetrasubstituted form of hGRF(1-29). The substitutions most commonly described in the literature are:

• D-Ala at position 2 — replaces the native Ala to reduce DPP-IV cleavage.
• Gln at position 8 — replaces Asn to improve stability.
• Ala at position 15 — replaces Gly to alter steric exposure.
• Leu at position 27 — replaces Met to reduce oxidative susceptibility.

These four changes are shared between CJC-1295 with DAC and Modified GRF (1-29). They are not the distinguishing feature. The distinguishing feature is the C-terminal extension.

The drug affinity complex (DAC)#

At the C terminus, CJC-1295 with DAC carries an Nε-3-maleimidopropionamide derivative of lysine. The maleimide group is a reactive moiety designed to bind covalently to the free thiol on cysteine-34 of serum albumin. After subcutaneous injection, the peptide circulates, encounters albumin, and forms a stable bioconjugate. Because albumin is abundant and long-lived in plasma, the conjugated peptide inherits a much longer apparent half-life than the free peptide would have on its own.

This mechanism was demonstrated in a foundational pharmacology paper in which CJC-1295 was identified from a panel of hGRF(1-29)–albumin bioconjugates. Western blot of rat plasma showed a CJC-1295–immunoreactive species on the albumin band within 15 minutes of injection, persisting beyond 24 hours. The compound remained detectable in plasma for more than 72 hours and produced a four-fold increase in growth-hormone area-under-the-curve over two hours compared with native hGRF(1-29) in that rat model (Jette et al., 2005).

Pharmacokinetic consequences#

The albumin-binding strategy changes the exposure profile from a short pulse to a sustained signal. In the literature, human pharmacodynamic observations following single injections of CJC-1295 with DAC have reported elevated plasma growth hormone for several days and elevated IGF-1 for one to two weeks. Multiple-dose observations have described IGF-1 elevations persisting for up to 28 days. These figures come from limited clinical pharmacology work rather than large randomised trials, and they should be treated as directional rather than definitive.

The key research implication is that CJC-1295 with DAC is not simply a more potent version of Sermorelin. It is a different temporal signal. A protocol designed to study acute GH pulsatility may be confounded by a sustained GHRH-receptor stimulus. A protocol designed to study chronic axis activation may find the extended exposure useful, but only if the researcher explicitly models the prolonged half-life in the study design.

The evidence map: four literatures, not one promise#

A serious research review separates the evidence into distinct layers.

Layer one: bioconjugation and pharmacokinetic design#

The earliest public literature on CJC-1295 with DAC is a pharmacology and medicinal-chemistry paper that explains the albumin-conjugation concept. The authors synthesised maleimido derivatives of hGRF(1-29), conjugated them ex vivo to human serum albumin, and showed that the conjugates resisted DPP-IV degradation while retaining bioactivity in cultured rat anterior pituitary cells. In vivo, CJC-1295 produced acute GH secretion and remained in circulation far longer than the native peptide. The paper concludes that CJC-1295 is a stable, active, long-lasting GRF analog with an extended plasma half-life (Jette et al., 2005).

This layer is important because it establishes the mechanism. The peptide is not magically long-acting; it is engineered to bind albumin. That engineering has consequences for batch-to-batch consistency, because the maleimide reactivity and conjugation efficiency must be controlled during synthesis and verified analytically.

Layer two: murine growth and body-composition studies#

A subsequent study in GHRH-knockout mice examined whether once-daily administration of CJC-1295 could normalise growth in animals with isolated GH deficiency. The results showed that daily injections for five weeks completely normalised body weight, naso-anal length, femur length, tibia length, and body composition (lean mass and subcutaneous fat) compared with heterozygote controls. Treatment every 48 hours produced intermediate growth results but still normalised bone length and body composition. Treatment every 72 hours improved growth versus placebo but did not fully normalise longitudinal growth. The compound also increased pituitary total RNA, GH mRNA, GH protein, and somatotroph cell proliferation in a dose-interval-dependent manner (Alba et al., 2006).

This layer is useful because it demonstrates efficacy in a defined genetic model, but it is not direct evidence for human therapeutic application. Species differences in albumin binding, DPP-IV activity, GH-axis set points, and metabolic clearance mean that murine data should inform mechanistic hypotheses rather than dosing expectations.

Layer three: human pharmacodynamic observations#

Human data on CJC-1295 with DAC are more limited and come from small pharmacodynamic studies rather than large regulatory trials. Published observations have reported that single injections can increase plasma GH two- to ten-fold for six days or longer, and IGF-1 zero-point-five- to three-fold for nine to eleven days. Multiple doses have been associated with IGF-1 elevations lasting up to 28 days. These numbers appear in review and summary literature, but the underlying primary human studies are few and have not led to regulatory approval in Canada or elsewhere.

Notably, a Phase II clinical trial in lipodystrophy was discontinued after a subject died. The attending physician attributed the death to asymptomatic coronary artery disease with plaque rupture, deemed unrelated to the study drug, but research was halted as a precaution. That history is relevant because it underscores the gap between pharmacodynamic observation and approved therapeutic use.

Layer four: supplier market and stack literature#

The most commonly encountered "evidence" for CJC-1295 with DAC is supplier copy and community stack discussions. This literature is useful only as a signal of what researchers are buying and combining. It should not be confused with peer-reviewed pharmacology. When a supplier page claims that CJC-1295 with DAC "boosts IGF-1 for weeks," the responsible reader should ask: in what species, under what assay conditions, with what batch purity, and with what regulatory status? Without those answers, the claim is advertising, not science.

CJC-1295 with DAC versus Modified GRF (1-29)#

The most common source of confusion in the growth-hormone peptide category is the conflation of CJC-1295 with DAC and Modified GRF (1-29), which is often sold as "CJC-1295 without DAC." The two molecules share the same tetrasubstituted hGRF(1-29) core, but they diverge at the C terminus.

That distinction should shape protocol design. A study that intends to examine acute GH pulsatility, GHRH-GHRP synergy, or discrete secretagogue timing should not substitute the long-acting analogue for the short-acting fragment without redesigning the endpoints. Conversely, a study that intends to model sustained GHRH-receptor occupancy may find the DAC version appropriate, provided the longer half-life is explicitly accounted for in sampling schedules and washout periods.

CJC-1295 with DAC and Modified GRF (1-29) are also combined in different ways on the market. Some suppliers sell them as separate vials; others blend them with GHRP-family peptides such as Ipamorelin. A researcher who buys a blend should know exactly which CJC variant is inside, because the pharmacokinetic profile of the blend depends on it.

How CJC-1295 with DAC compares with other growth-hormone peptides#

The growth-hormone peptide archive is strongest when each article does a different job. The pillar guide maps the whole category. The Sermorelin article covers the historical GHRH fragment. The Ipamorelin article covers selective GHSR framing. The CJC-1295/Ipamorelin blend article covers a common combined pair. This article adds the missing long-acting GHRH analogue guide.

Comparison with Sermorelin#

Sermorelin is the historical GHRH(1-29) fragment. It is short-acting, unsubstituted at the four positions that protect CJC-1295 from DPP-IV, and not designed for albumin binding. Sermorelin is useful for protocols that study native GHRH-receptor pharmacology or that require rapid clearance. CJC-1295 with DAC is useful for protocols that require sustained exposure. They are not dose-equivalent.

Comparison with Tesamorelin#

Tesamorelin is a clinical GHRH analogue with a regulated history in HIV-associated lipodystrophy. It has a different sequence modification (a trans-3-hexenoic acid group on Tyr) and a different clinical evidence base. CJC-1295 with DAC has not undergone the same regulatory scrutiny and should not be treated as a generic substitute for Tesamorelin in research designs that reference clinical endpoints.

Comparison with Ipamorelin, GHRP-2, GHRP-6, and Hexarelin#

These compounds belong in the GHRP/GHSR lane, not the GHRH-receptor lane. They stimulate the ghrelin receptor rather than the GHRH receptor. CJC-1295 with DAC can be combined with a GHRP-family peptide in research protocols that study dual-pathway synergy, but the combination is not automatically superior. The rationale must state why sustained GHRH signalling plus intermittent GHSR signalling is the correct model for the endpoint being measured.

Comparison with MK-677#

MK-677 is a non-peptide oral ghrelin-receptor agonist. It is not a GHRH analogue, it is not albumin-binding, and its pharmacokinetics are entirely different. The only similarity is that both compounds can influence the GH axis. Researchers should not conflate them in protocols or in supplier comparisons.

Sourcing and quality-control cautions for Canadian researchers#

Because CJC-1295 with DAC is a modified peptide with a reactive maleimide group, purity and identity verification are especially important. A batch with incomplete conjugation chemistry, residual reagents, or incorrect sequence could behave differently from the compound described in the literature.

Documentation red flags#

The first red flag is a supplier page that lists only "CJC-1295, 99% purity" without specifying whether the product is the DAC or no-DAC form. The two molecules have different molecular weights, different HPLC profiles, and different research applications. A listing that does not declare the DAC status is not suitable for serious research.

The second red flag is the absence of lot-matched analytical data. A credible supplier should provide:

• HPLC chromatogram showing purity for the specific lot.
• Mass spectrometry confirming the expected molecular weight.
• Declared sequence or structural identity matching the tetrasubstituted hGRF(1-29)-DAC construct.
• Salt form and fill amount clearly stated.
• Storage conditions appropriate for a peptide conjugate.
• Research-use-only language on the product page and vial label.

The third red flag is therapeutic or wellness marketing. CJC-1295 with DAC is not an approved drug in Canada for anti-ageing, body-composition improvement, or hormone replacement. Any supplier that implies clinical efficacy or provides dosing instructions for human use is operating outside research-use norms.

Shipping and stability considerations#

Canadian researchers should consider temperature exposure during shipping, especially in summer months. Peptides are typically shipped lyophilised and should remain cold during transit. Upon receipt, they should be stored according to the supplier's guidance — usually frozen or refrigerated for long-term stability. The maleimide-albumin binding chemistry is an in vivo event; the lyophilised vial contains the reactive peptide, not the albumin conjugate, so stability is governed by peptide chemistry rather than conjugate dissociation.

Frequently asked questions#

How this guide fits the Northern Compound archive#

The growth-hormone category is strongest when each molecule has its own clear research identity. The pillar guide provides the map. The Sermorelin article explains the short-acting GHRH fragment. The Ipamorelin article explains selective GHSR framing. The CJC-1295/Ipamorelin blend article explains a popular combined pair. The Tesamorelin article covers a clinically recognisable GHRH analogue. This guide fills the remaining gap: the long-acting, albumin-binding GHRH analogue that is frequently mentioned but rarely examined on its own terms.

That editorial role matters for search intent. A reader searching "CJC-1295 DAC Canada" is often close to a product decision but may not understand the pharmacokinetic distinction that separates the DAC form from the no-DAC form. The responsible answer is not a pushy buying page. It is a decision framework: understand the molecule, separate the evidence layers, compare it with neighbouring compounds, reject unsupported claims, and verify the source. Product links are useful only when they sit inside that framework.

For that reason, this guide links to relevant Lynx product pages with attribution while keeping the article independent in tone. Readers can inspect CJC-1295 with DAC, Modified GRF (1-29), Sermorelin, and Ipamorelin listings, but the article's conclusion is not "buy the longest-acting one." The conclusion is that the right compound depends on receptor intent, exposure profile, endpoint design, and supplier documentation.

That is the standard Northern Compound should apply across the archive: useful enough for commercial search traffic, cautious enough for research-use-only compliance, and specific enough that a serious reader learns something beyond the product name.